Bayer, Onyx: Nexavar fails in lung cancer study
WAYNE, N.J. A drug made by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals failed to extend overall survival of a group of lung cancer patients, according to results of a late-stage clinical trial announced Monday.
The two companies said the tablet drug Nexavar (sorafenib) did not improve overall survival as a first-line treatment for patients with advanced non-squamous non-small cell lung cancer in a phase 3 trial comparing Nexavar with placebo combined with chemotherapy. The drug already is approved to treat kidney cancer.
“Bayer and Onyx are disappointed with these results, in particular, for patients who are suffering from this deadly disease,” Bayer HealthCare VP global clinical development for oncology Dimitris Voliotis said. “We are confident in our clinical trial program exploring Nexavar’s potential in a variety of tumor types, including lung cancer.”
Kroger kicks off Bringing Hope to the Table campaign
CINCINNATI Retail giant Kroger is inviting customers to help hungry people in their own communities by joining its two week-long campaign in its family of stores.
Kroger said its Bringing Hope to the Table campaign is expected to generate $4 million dollars in cash and food donations to assist 80 local food banks in communities where Kroger’s customers and associates live and work. Participating items will be marked with yellow shelf tags to indicate their pledge to support Bringing Hope to the Table.
“Through Bringing Hope to the Table, our customers, associates and vendors can drive funds to food banks that feed hungry people in their own communities,” said Lynn Marmer, Kroger’s group VP corporate affairs. “In 2009, Kroger stores partnered with customers and vendors to donate enough food to serve 40 million meals to feed hungry families in the communities we serve.”
New survey finds affluent consumers drive economic recovery
BOSTON A new consumer study underscored the role affluent consumers play in driving the economy toward recovery.
Consulting firm L.E.K.’s consumer sentiment survey polled 2,000 U.S. households in April and found that more than one-third (39%) of affluent consumers — those households making more than $150,000 annually — believed their spending was either not impacted materially by the recession or already has returned to pre-recession spending levels, making them drivers in the economic recovery. The general population is significantly more cautious, with only 12% expecting their personal finances to improve by fall 2010, while 65% don’t anticipate that their finances will rebound significantly for the next 12 to 24 months.
According to the L.E.K. research, the affluent consumer is the only demographic that is spending more today than before the recession, and is the only group planning more purchases (expected 3.5% increase) in the near future. Furthermore, affluent consumers are more likely to purchase organic and natural food, “green” products and selectively splurge on higher-end brands, hence driving those retail categories to grow.
“L.E.K.’s survey findings show that wealthy consumer spending is outpacing the general public significantly and appears to be literally pulling the United States out of its recession,” said Andrew Rees, VP and head of the L.E.K. consulting retail practice. “The distinct affluent demographic underscores why retailers need to truly understand what motivates each customer type. Deep customer segmentation will give retailers the insight to chart a clear course despite hazy market conditions.”